Sidney Lupkin

It treats prescription pills like some cancer drugs differently from more complex biotech drugs like the blockbuster rheumatoid arthritis drug, Humira. The pills are eligible for Medicare negotiation sooner, seven years after FDA approval, compared with 11 years for drugs like Humira. The proposal would level the playing field, but it would require a change in the law.

It treats prescription pills like some cancer drugs differently from more complex biotech drugs like the blockbuster rheumatoid arthritis drug, Humira. The pills are eligible for Medicare negotiation sooner, seven years after FDA approval, compared with 11 years for drugs like Humira. The proposal would level the playing field, but it would require a change in the law.

It treats prescription pills like some cancer drugs differently from more complex biotech drugs like the blockbuster rheumatoid arthritis drug, Humira. The pills are eligible for Medicare negotiation sooner, seven years after FDA approval, compared with 11 years for drugs like Humira. The proposal would level the playing field, but it would require a change in the law.

Yeah, it does. There's a lot in the executive action. It has 14 different sections. It takes aim at middlemen called pharmacy benefit managers, which handle drug coverage for health insurance. The order tells officials to look for ways to increase transparency into how they're compensated. The companies have been criticized for not passing on savings to consumers.

Yeah, it does. There's a lot in the executive action. It has 14 different sections. It takes aim at middlemen called pharmacy benefit managers, which handle drug coverage for health insurance. The order tells officials to look for ways to increase transparency into how they're compensated. The companies have been criticized for not passing on savings to consumers.

Yeah, it does. There's a lot in the executive action. It has 14 different sections. It takes aim at middlemen called pharmacy benefit managers, which handle drug coverage for health insurance. The order tells officials to look for ways to increase transparency into how they're compensated. The companies have been criticized for not passing on savings to consumers.

It also instructs the FDA to streamline its generic drug approvals process and to better facilitate state programs to import lower-cost drugs from Canada. The drug importation push actually started under the first Trump administration, and it just hasn't gotten much traction.

It also instructs the FDA to streamline its generic drug approvals process and to better facilitate state programs to import lower-cost drugs from Canada. The drug importation push actually started under the first Trump administration, and it just hasn't gotten much traction.

It also instructs the FDA to streamline its generic drug approvals process and to better facilitate state programs to import lower-cost drugs from Canada. The drug importation push actually started under the first Trump administration, and it just hasn't gotten much traction.

bit in this executive order is familiar. The first Trump administration made several attempts to lower drug prices, and that included importing drugs from Canada and speeding generic approvals. It also proposed pegging drug prices in the U.S. to lower prices paid in other countries, but that didn't happen. So when it came to drug prices as a campaign issue last year, Trump didn't say much.

bit in this executive order is familiar. The first Trump administration made several attempts to lower drug prices, and that included importing drugs from Canada and speeding generic approvals. It also proposed pegging drug prices in the U.S. to lower prices paid in other countries, but that didn't happen. So when it came to drug prices as a campaign issue last year, Trump didn't say much.

bit in this executive order is familiar. The first Trump administration made several attempts to lower drug prices, and that included importing drugs from Canada and speeding generic approvals. It also proposed pegging drug prices in the U.S. to lower prices paid in other countries, but that didn't happen. So when it came to drug prices as a campaign issue last year, Trump didn't say much.

This is really the first time in a while we're hearing about drug prices. Here's Juliet Kubanski, a Medicare drug pricing expert at the nonpartisan research group KFF.

This is really the first time in a while we're hearing about drug prices. Here's Juliet Kubanski, a Medicare drug pricing expert at the nonpartisan research group KFF.

This is really the first time in a while we're hearing about drug prices. Here's Juliet Kubanski, a Medicare drug pricing expert at the nonpartisan research group KFF.

High drug prices are a big deal to voters, whether they're Democrats or Republicans.

High drug prices are a big deal to voters, whether they're Democrats or Republicans.

High drug prices are a big deal to voters, whether they're Democrats or Republicans.

You know, that's unclear. Executive orders can only do so much. In this case, the action is telling the FDA to take certain steps, instructing his HHS secretary to work with Congress, instructing officials to come up with regulatory solutions. So a lot will depend on all these different players working together.

You know, that's unclear. Executive orders can only do so much. In this case, the action is telling the FDA to take certain steps, instructing his HHS secretary to work with Congress, instructing officials to come up with regulatory solutions. So a lot will depend on all these different players working together.